TRCT
CPHI icon

Tower Research Capital (TRC)’s China Pharma Holdings CPHI Stock Holding History

Tower Research Capital (TRC)’s Portfolio CPHI Stock Details CPHI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,213
Closed -$14.7K – 5270
2025
Q2 		$14.7K Buy
+8,213
New +$15.1K ﹤0.01% 3828

Other funds holding CPHI

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Tower Research Capital (TRC)'s CPHI Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of China Pharma Holdings (CPHI) in Q3 2025, closing a stake of 8,213 shares — an estimated $14.7K sold.

Tower Research Capital (TRC) first reported a position in CPHI in Q2 2025 and held it in 1 quarter. The position peaked at $14.7K in Q2 2025. 5 funds tracked by Wall St. Rank hold CPHI as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining China Pharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,213 China Pharma Holdings shares in Q3 2025, an estimated $14.7K.
  • Tower Research Capital (TRC) first reported a position in China Pharma Holdings in Q2 2025 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s China Pharma Holdings position peaked at $14.7K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held China Pharma Holdings as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.